Report Highlights
The global cardiac biomarkers market has grown to $4.9 billion in 2015 from $4.4 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.
Report Includes
- An overview of the global market for cardiac biomarkers and related technologies.
- Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
- Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
- Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
- Clinical guidelines and government regulations.
- Profiles of major players in the industry.
Report Scope
Current and projected assay revenues during the forecast period (2015 through 2020) are presented. In addition, newly developed assays with regulatory approval and others expected to receive U.S. Food and Drug Administration approval within the forecast period are also projected. Figures for 2015 are estimated, except where actual results have been reported, because of the timing of the release of this report. For large market segments, such as cTn and natriuretic peptides, the analytical sensitivities and cutoff references for the diagnosis and prognosis values are discussed in detail. Moreover, the ongoing effort in developing a high-sensitivity troponin assay, as well as the attempt to pursue additional biomarkers for the diagnosis of congestive heart failure (CHF) and strokes are focused on in this study.
The report includes an analysis of leading and emerging competitors in the current global diagnostics market for CVDs. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed to define their specific product strategies. The competitive environment is examined, with a special focus on how instrumentation type (clinical chemistry analyzers compared with point-of-care devices) and their respective technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to enter the market during the forecast period.
Market figures are based on revenues at the manufacturers’ level and are projected at 2015-U.S.-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence and diagnosis of respective diseases. Included in this report are forecasts by product, product category and by company from 2014 through 2020. The study is arranged to offer an overview of the diagnostics market accompanied by product, company and region.
Excluded from this report are nonproteomic diagnoses (i.e., molecular diagnostics), imaging technology and pharmaceutical biomarkers. Sales figures are reported in U.S. dollars, and in each case, these reflect currency fluctuations within the performance of changes in sales. Sales figures do not account for variation in local currencies. All market share data presented are on a global basis, unless specifically noted.
Analyst Credentials
ANUJ PATHAK has written and researched the global medical device market, surgical instruments and biotechnology market. Skilled in information technology and computer management, he has an undergraduate business degree and an MBA degree.
Report Highlights
The global market for in vitro diagnostic tests for cardiac biomarkers was estimated at $3.1 billion in 2012 and nearly $4 billion in 2013. This market is predicted to reach $7.2 billion by 2018, at a compound annual growth rate (CAGR) of 12.8% over the five-year period from 2013 to 2018.
Report Includes
- An overview of the global market for biomarkers for cardiovascular disease (CVD) and related technologies.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs for the period 2013 to 2018.
- Classification of CVD by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
- Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
- Clinical guidelines and government regulations.
Related Reports
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Biomarkers: Technologies and Global Markets
The global market for biomarkers should grow from $43.3 billion in 2020 to $92.1 billion by 2025, at compound annual growth rate (CAGR) of 16.3% for the period of 2020-2025.
Cardiovascular Devices: Global Markets to 2022
The global market for cardiovascular devices reached nearly $42.4 billion in 2017 and should reach $59.1 billion by 2022, at a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.
Emerging Diagnostic Technologies in the Changing U.S. Market
The U.S. emerging diagnostic technologies market was valued at $880 million in 2011 and should reach $1.2 billion in 2012. Total market value is expected to reach $3.2 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 20.9%.
Recent Reports
Bioprocess Optimization and Digital Bio-manufacturing: Global Markets
The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.
Global DNA Sequencing: Research, Applied and Clinical Markets
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More